<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080244</url>
  </required_header>
  <id_info>
    <org_study_id>2021-3700-ECR</org_study_id>
    <nct_id>NCT05080244</nct_id>
  </id_info>
  <brief_title>WHO COVID-19 - Evaluation of the Efficacy of Probiotics to Reduce the Occurrence of Long COVID</brief_title>
  <acronym>PROVID-LD</acronym>
  <official_title>Evaluation of the Efficacy of Probiotics Taken During the Acute Phase of COVID-19 to Reduce the Occurrence of Long COVID</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lallemand Health Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Probiotics may be considered as an option of treatment for long COVID since they have&#xD;
      anti-viral effect, trigger immunomodulation and have low side-effects. This randomized&#xD;
      controlled trial aims to reduce the number of patients with long COVID by 25% 90 days after&#xD;
      the COVID-19 diagnosis by taking probiotics in a symptomatic population, self-caring at home.&#xD;
      During the acute phase of the disease, participants will take two capsules (probiotics or&#xD;
      placebo) per day for 10 days and one capsule (probiotics or placebo) per day for the&#xD;
      following 15 days. A follow-up will be done twice during the acute phase, 14 days and 28 days&#xD;
      after starting to take the investigational product (compliance to treatment, side effects,&#xD;
      etc.). At inclusion and at Day14, Day30 and Day90 after the COVID-19 diagnosis, a&#xD;
      questionnaire will be administered (COVID-19 symptoms, anxiety, functioning difficulties,&#xD;
      etc.) and 2 saliva and 2 stool (viral and microbiota analyzes) self-samples will be&#xD;
      performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rational:&#xD;
&#xD;
      COVID-19 disease caused by a new coronavirus (SARS-CoV-2) has received worldwide attention.&#xD;
      No effective treatment against COVID-19 is available and the current vaccination appears&#xD;
      essential to control the pandemic. However, many questions remain, such as the durability of&#xD;
      immunity and the appearance of variants. While the acute phase has been widely studied, the&#xD;
      long-term consequences are unknown, and a new burden is emerging: the long COVID. The long&#xD;
      COVID is defined by the persistence of symptoms of the disease for more than 4 weeks after&#xD;
      diagnosis. Several strong arguments support the study of probiotics for COVID-19: 1)&#xD;
      probiotics act on viruses by various well described mechanisms (reduction of absorption,&#xD;
      cellular internalization of the virus, production of metabolites/substances having a direct&#xD;
      antiviral effect and immunomodulation); 2) probiotics are considered with a high level of&#xD;
      evidence (meta-analysis) to reduce diarrhea (associated with antibiotics and Clostridium&#xD;
      difficile) and for respiratory tract infections and 3) probiotics are affordable and&#xD;
      available with low side-effects.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary objective: Reduce the number of patients with long COVID by 25% 90 days after the&#xD;
      COVID-19 diagnosis by taking probiotics during the acute phase of the disease.&#xD;
&#xD;
      Secondary objectives (SO).&#xD;
&#xD;
      SO1: Reduce the number of patients with long COVID by 25% 30 days after the COVID-19&#xD;
      diagnosis by taking probiotics during the acute phase of the disease.&#xD;
&#xD;
      SO2: Improve the understanding of the mechanism of action of probiotics on long COVID from&#xD;
      salivary and fecal virological and microbiota analyzes.&#xD;
&#xD;
      SO3: Identify the prognostic factors measured at the baseline (inclusion) associated with&#xD;
      long COVID (socio-demographic, clinical, virological, microbiological factors) and the&#xD;
      time-dependent factors after the baseline.&#xD;
&#xD;
      Population:&#xD;
&#xD;
      618 men and women, 18 years or older, with a first positive test for COVID-19 in the last 10&#xD;
      days, having symptoms of the COVID-19, self-caring at home, living in Quebec for the next 90&#xD;
      days, able to take medication alone, with access to a phone or to the Internet.&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
      Patients will be randomized in one of the study groups (stratified by age and gender). The&#xD;
      randomization is double-blinded and uses a ratio 1:1. Group A: will take probiotics for 25&#xD;
      days / Group B: will take placebo for 25 days.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      During the acute phase of the disease, participants will take two capsules (probiotics or&#xD;
      placebo) per day (one closed capsule to swallow and one open capsule mixed with maple syrup)&#xD;
      for 10 days and one closed capsule (probiotics or placebo) per day to swallow for the&#xD;
      following 15 days.&#xD;
&#xD;
      Data collection:&#xD;
&#xD;
      A follow-up will be done twice during the acute phase, 14 days and 28 days after starting to&#xD;
      take the investigational product to evaluate compliance to treatment, medication intake, side&#xD;
      effects, etc. At inclusion and at Day14, Day30 and Day90 after the COVID-19 diagnosis, the&#xD;
      participant will complete a questionnaire that will focus on COVID-19 symptoms, food intake,&#xD;
      anxiety, functioning difficulties, quality of life, etc. For those who will be admitted to&#xD;
      hospital, data on their admission, complications and treatments will be collected.&#xD;
&#xD;
      Samples:&#xD;
&#xD;
      At inclusion and at Day14, Day30 and Day90 after the COVID-19 diagnosis, 2 saliva and 2 stool&#xD;
      (viral and microbiota analyzes) self-samples will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with long COVID 90 days after the COVID-19 diagnosis</measure>
    <time_frame>90 days after the COVID-19 diagnosis.</time_frame>
    <description>COVID-19 symptoms (FLU-PRO), anxiety (GAD-7) and functioning difficulties (WG-SS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with long COVID 30 days after the COVID-19 diagnosis</measure>
    <time_frame>30 days after the COVID-19 diagnosis.</time_frame>
    <description>COVID-19 symptoms (FLU-PRO), anxiety (GAD-7) and functioning difficulties (WG-SS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe and compare the salivary and fecal microbiota of patients on probiotics or placebo according to the progression of long COVID.</measure>
    <time_frame>Inclusion, Day14, Day30 and Day90 after the COVID-19 diagnosis</time_frame>
    <description>Microbiota analyzes (Metagenomic sequencing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the salivary and fecal viral load of patients on probiotics or placebo according to the progression of long COVID.</measure>
    <time_frame>Inclusion, Day14, Day30 and Day90 after the COVID-19 diagnosis</time_frame>
    <description>Viral load analyzes (qPCR).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">618</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two probiotic strains will constitute the experimental arm (Probiotics). Participants will take two capsules per day (one closed capsule to swallow and one open capsule mixed with maple syrup) for 10 days and one closed capsule per day to swallow for the following 15 days. They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Potato starch and magnesium stearate will constitute the comparator arm (Placebo). Participants will take two capsules per day (one closed capsule to swallow and one open capsule mixed with maple syrup) for 10 days and one closed capsule per day to swallow for the following 15 days. They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>2 strains 10x10^9 UFC/capsule</description>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Potato starch and magnesium stearate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years and over&#xD;
&#xD;
          -  â‰¤ 10 days between the COVID-19 diagnosis and the inclusion&#xD;
&#xD;
          -  Having symptoms of the COVID-19 at inclusion&#xD;
&#xD;
          -  Living in Quebec for the next 90 days&#xD;
&#xD;
          -  Self-caring at home&#xD;
&#xD;
          -  Able to take medication alone&#xD;
&#xD;
          -  With access to a phone or to the Internet&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking probiotic supplements at inclusion&#xD;
&#xD;
          -  Taking antibiotics for a reason other than COVID-19 at inclusion&#xD;
&#xD;
          -  Allergies to soy, lactose, yeast, maltodextrin, vitamin C, potato starch, magnesium&#xD;
             stearate, hypromellose or titanium dioxide&#xD;
&#xD;
          -  Has a chronically weakened immune system (AIDS, lymphoma, chemo-radio-corticosteroid&#xD;
             therapy, immunosuppressive pathology)&#xD;
&#xD;
          -  Was treated with chemo-radio-corticosteroid therapy in the last 6 months&#xD;
&#xD;
          -  Has active cancer&#xD;
&#xD;
          -  Taking immunosuppressive drugs (e.g. anti-rejection treatment after organ transplant)&#xD;
&#xD;
          -  Already participating in another randomized clinical trial&#xD;
&#xD;
          -  Is pregnant, expects to become pregnant in the next few months or is breastfeeding&#xD;
&#xD;
          -  Has any other condition that would prevent safe participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Charles Pasquier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIUSSSE-CHUS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Audrey Hamel-Thibault, MSc</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>12865</phone_ext>
    <email>Audrey.Hamel-Thibault@USherbrooke.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Blanche Senicourt, PhD</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>13877</phone_ext>
    <email>Blanche.Senicourt@USherbrooke.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIUSSS de L'Estrie-CHUS Hospital</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Hamel-Thibautl, MSc</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>12865</phone_ext>
      <email>Audrey.Hamel-Thibault@USherbrooke.ca</email>
    </contact>
    <contact_backup>
      <last_name>Blanche Senicourt, PhD</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>13877</phone_ext>
      <email>Blanche.Senicourt@USherbrooke.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Charles Pasquier, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Long COVID</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Sars-CoV-2</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

